

Neurochemicals for the Investigation of GABA_C Receptors

Graham A. R. Johnston · Mary Chebib ·
Jane R. Hanrahan · Kenneth N. Mewett

Accepted: 13 September 2010 / Published online: 21 October 2010
© Springer Science+Business Media, LLC 2010

Abstract GABA_C receptors are being investigated for their role in many aspects of nervous system function including memory, myopia, pain and sleep. There is evidence for functional GABA_C receptors in many tissues such as retina, hippocampus, spinal cord, superior colliculus, pituitary and the gut. This review describes a variety of neurochemicals that have been shown to be useful in distinguishing GABA_C receptors from other receptors for the major inhibitory neurotransmitter GABA. Some selective agonists (including (+)-CAMP and 5-methyl-IAA), competitive antagonists (such as TPMPA, (±)-*cis*-3-ACPBPA and aza-THIP), positive (allopregnanolone) and negative modulators (epipregnanolone, loreclezole) are described. Neurochemicals that may assist in distinguishing between homomeric $\rho 1$ and $\rho 2$ GABA_C receptors (2-methyl-TACA and cyclothiazide) are also covered. Given their less widespread distribution, lower abundance and relative structural simplicity compared to GABA_A and GABA_B receptors, GABA_C receptors are attractive drug targets.

Keywords GABA · GABA_C · TPMPA · Allopregnanolone · Loreclezole · Cyclothiazide

Abbreviations

Aza-THIP	4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-3-ol
CACA	cis-4-aminocrotonic acid
(+)-CAMP	(1S,2R)-2-aminomethylcyclopropanecarboxylic acid
(±)- <i>cis</i> -3-ACPBPA	(±)- <i>cis</i> -(3-aminocyclopentanyl)butylphosphinic acid
5-Me-IAA	5-methyl-1H-imidazole-4-acetic acid
2-Methyl-TACA	<i>trans</i> -4-amino-2-methylbut-2-enoic acid
P4MPA	(piperidin-4-yl)methylphosphinic acid
SGS742	(3-aminopropyl)- <i>n</i> -butylphosphinic acid
THIP	4,5,6,7-tetrahydroisolazolo[5,4-c]pyridin-3-ol
TPMPA	(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid

Special issue article in honour of Dr. Abel Lajtha.

The authors are pleased to honour Abel Lajtha for his expert stewardship of this journal since its inception and his generous assistance to many Australian neurochemists.

G. A. R. Johnston (✉) · K. N. Mewett
Adrien Albert Laboratory of Medicinal Chemistry, Department of Pharmacology D06, The University of Sydney, Sydney, NSW 2006, Australia
e-mail: grahamj@mail.usyd.edu.au

M. Chebib · J. R. Hanrahan
Faculty of Pharmacy A15, The University of Sydney, Sydney, NSW 2006, Australia

Introduction

GABA_C receptors are being investigated for their role in many aspects of nervous system function including memory [1, 2], myopia [2, 3], pain [4] and sleep [5]. This review describes some representative neurochemicals that have been shown to be useful in distinguishing GABA_C receptors from other receptors for the major inhibitory neurotransmitter GABA, thus aiding in the investigation of

GABA_C receptors. It is concerned mainly with studies on human recombinant receptors as a model system for the study of ionotropic GABA receptors of known subunit composition. For a comprehensive listing of GABA analogs that have been examined on human recombinant GABA_C receptors, see the molecular modelling study by Abdel-Halim et al. [6].

The origin of the concept of GABA_C receptors was the observation that CACA, *cis*-4-aminocrotonic acid (Fig. 1), inhibited the firing of cat spinal neurones in a manner insensitive to the GABA_A antagonist bicuculline [7]. As CACA did not influence the binding of the GABA_B agonist (–)-baclofen to rat brain membranes, this led to the suggestion that it was interacting with ‘a class of binding site (GABA_C?)’ insensitive to (–)-baclofen and bicuculline [8]. The cloning of ρ 1 [9, 10] and ρ 2 receptors [11] together with the commercial availability of CACA led to a surge in studies on GABA_C receptors. A third GABA_C subtype ρ 3 was subsequently cloned from rat retina [12]. GABA_C receptors differ from GABA_A and GABA_B receptors on the basis of their significant physiological, pharmacological and molecular biological differences [13].

Genetic linkage and radiation hybrid mapping of the three human GABA_C receptor subunit genes, GABRR1, GABRR2 and GABRR3, have shown that GABRR1 and GABRR2 are located close together, in a region of chromosome 6q that contains loci for inherited disorders of the eye, while GABRR3 maps to chromosome 3q11-q3.3 [14]. The mapping data suggests that the GABA_C receptor subunit genes, which share a common ancestor with GABA_A receptor subunit genes, diverged at an early stage in the evolution of this gene family with the GABA_C and GABA_A genes being located on different chromosomes [14]. Most neurochemical studies have been carried out on the ρ 1 and to a lesser extent the ρ 2 subtype of GABA_C receptors, while only limited studies have been done on the ρ 3 subtype. The bulk of these studies were on homomeric receptors although there is some evidence for heteromeric GABA_C receptors made up of more than one ρ -subtype [15] and there is also evidence that all three ρ -subtypes occur in the same hippocampal neurones [16]. Polyclonal antibody studies suggest that GABA_C receptors do not co-assemble with either GABA_A or glycine receptor subunits in rat retina [17].

There is evidence for functional GABA_C receptors in many tissues such as the retina, hippocampus, spinal cord, superior colliculus, pituitary and the gut [18]. The most extensive studies have been carried out in vertebrate retina [19]. Knockout studies show that elimination of the ρ 1 subunit alters visual processing in mouse retina [20] and leads to changes in vascular permeability similar to the pathological changes induced by hypoxic conditions seen in diabetic retinopathy [21]. Knockout studies also show that ρ 1 GABA_C receptors mediate inhibitory modulation on the olfactory bulb [22] and that GABA_C receptor mediated inhibition is altered, but not eliminated, in the superior colliculus suggesting that ρ 2 or ρ 3 GABA_C receptors are functional in this tissue [23]. Knockout studies on the ρ 2 GABA_C receptor in mice suggest the involvement of these receptors in pain pathways [24]. Both ρ 1 and ρ 2 GABA_C receptors are found in the hippocampus where there is evidence for their functional role as extra-synaptic receptors activated via spillover of synaptically released GABA [25] and in paired-pulse depression of inhibitory postsynaptic currents [26]. GABA_C receptors may be involved in the regulation of thyrotropin release from the pituitary [27] and in synaptic transmission in the spinal cord [28]. GABA_C receptors have also been described on neurones in the gastrointestinal system [29] where they may increase the release of nitric oxide from non-adrenergic, non-cholinergic inhibitory neurones [30].

GABA_C Agonists

The prototype GABA_C neurochemical, CACA, proved to be a partial agonist at human recombinant GABA_C receptors expressed in *Xenopus* oocytes showing 70–80% of the efficacy of GABA and equally potent on ρ 1 and ρ 2 receptors (EC₅₀ 70–74 μ M) [31, 32]. Subsequently, CACA was found to have other actions including effects on GABA transport [33–35] and α 6-containing GABA_A receptors in the cerebellum [36]. Thus, CACA should be used with care as a selective GABA_C agonist.

(+)-CAMP, (1*S*,2*R*)-2-aminomethylcyclopropanecarboxylic acid (Fig. 1), is a more selective GABA_C agonist than CACA [37]. It is a full agonist at recombinant GABA_C receptors, more potent at ρ 2 (K_d 27 μ M) than at ρ 1 (K_d 40 μ M) and does not influence GABA transport. It shows little activity at α 1 β 2 γ 2L GABA_A receptors. While both CACA and (+)-CAMP are conformationally restricted analogs of GABA in a folded conformation, conformational restriction in (+)-CAMP is achieved via a cyclopropane ring, rather than a *cis* double bond as in CACA. This has less influence on the ionisation of the carboxyl group, which is thus more acidic in CACA than in (+)-CAMP and GABA. (–)-CAMP, the enantiomer of




Fig. 1 Structures of some representative agonists at GABA_C receptors

(+)-CAMP, surprisingly shows the opposite pharmacology at GABA_C receptors being a weak antagonist (IC₅₀ 900 and 400 μ M at ρ 1 and ρ 2 receptors respectively) [37]. Rarely do enantiomers exert opposite pharmacological effects as in this case. The difficulty of separating the CAMP enantiomers means that supplies of enantiomerically pure (+)-CAMP are limited.

5-Me-IAA, 5-methyl-1H-imidazole-4-acetic acid (Fig. 1), is a full agonist that is more potent than (+)-CAMP at human ρ 1 GABA_C receptors expressed in HEK293 cells (EC₅₀ 22 and 40 μ M for 5-Me-IAA and (+)-CAMP respectively) [38]. It shows little activity at α 1 β 2 γ 2S GABA_A receptors. Extensive structure–activity studies on substituted imidazole acetic acid derivatives together with mutagenesis and molecular modelling studies indicated that a major difference in the orthosteric sites of α 1 β 2 γ 2S GABA_A and ρ 1 GABA_C receptors is a threonine residue (Thr129) in the α 1 subunit and a serine (Ser168) residue in the equivalent position in ρ 1. The larger size of the threonine may hinder access of 5-Me-IAA to the orthosteric sites of α 1 β 2 γ 2S GABA_A receptors [38]. 5-Me-IAA, or a related 5-substituted imidazole-4-acetic acid derivative, may well be the agonist of choice with which to study GABA_C receptors but more studies need to be carried out.

GABA_C Competitive Antagonists

Agents that are structurally related to GABA that competitively inhibit the activation of GABA receptors by GABA are considered to be competitive antagonists acting at the GABA orthosteric site, as distinct from negative modulators that act at allosteric sites [39].

TPMPA, (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (Fig. 2), was the first selective GABA_C antagonist to be developed and widely used [40, 41]. It shows more than 100 fold selectivity in blocking ρ 1 GABA_C than α 1 β 2 γ 2 GABA_A receptors. It is some 8 times less potent at ρ 2 than at ρ 1 GABA_C receptors [42]. The piperidine analog of TPMPA, P4MPA ((piperidin-4-yl)methylphosphinic acid, Fig. 2), shows the reverse selectivity being more potent at ρ 2 than at ρ 1 GABA_C receptors [43].

TPMPA and related GABA_C antagonists have been patented for the treatment of myopia [3]. TPMPA has been used to study GABA_C receptor function in the retina [44], cerebral cortex zone [45], cerebellum [46], hippocampus [26], lateral geniculate nucleus [47], superior colliculus [48], spinal cord [28], anterior pituitary [49] and duodenum [30]. It has been used to study the involvement of GABA_C receptors in sleep-waking behavior [5] and in antinociception in the periphery [4]. Intracranial injections of TPMPA and P4MPA have been used to study the role of




Fig. 2 Structures of some GABA_C receptor antagonists

GABA_C receptors in short term memory formation in young chicks [1], however it is not clear whether or not TPMPA crosses the blood brain barrier on systemic administration.

Several phosphinic, phosphonic and seleninic acid bioisosteres of isonipecotic acid act as novel and selective GABA_C antagonists, with piperidin-4-ylseleninic acid (SEPI) being more potent than TPMPA [50].

SGS742, (3-aminopropyl)-n-butylphosphinic acid (Fig. 2), also known as CGP36742, is one of a range of phosphinic acid analogs of GABA that act as GABA_C antagonists [51]. It was developed as an orally active GABA_B receptor antagonist [52] and showed therapeutic potential for the treatment of cognitive deficits, petit mal epilepsy and depression [53]. The discovery that it was also a GABA_C receptor antagonist with potency about half that at GABA_B receptors [51] led to the development of cyclopentane analogs in which the conformational flexibility of the 3-aminopropyl moiety was constrained. These cyclopentane analogs were inactive at GABA_B receptors but retained the GABA_C receptor antagonist activity of SGS742. Of particular interest was (±)-cis-3-ACPBPA, (±)-cis-(3-aminocyclopentyl)butylphosphinic acid (Fig. 2), which was shown to be a selective GABA_C antagonist that enhanced learning and memory following intraperitoneal injection in rats and inhibited the development of myopia on intravitreal injection in chicks [2]. (±)-cis-3-ACPBPA and related cyclopentane and cyclopentane analogs have been patented

for use in enhancing cognitive activity [54, 55]. They are lead compounds for further drug development.

2-Methyl-TACA, *trans*-4-amino-2-methylbut-2-enoic acid (Fig. 2), a known GABA_A agonist, is of interest as it has contrasting effects on $\rho 1$ and $\rho 2$ GABA_C receptors [42]. It is a competitive antagonist at $\rho 1$ GABA_C receptors (K_b 45 μ M) and a partial agonist at human $\rho 2$ GABA_C receptors (K_d 101 μ M, I_{max} 34%). It may be useful in distinguishing between native homomeric $\rho 1$ and $\rho 2$ GABA_C receptors in vitro.

THIP (Gaboxadol) is widely used as a GABA_A receptor partial agonist of high efficacy [56]. It is of particular interest as a non-opioid analgesic and a novel hypnotic agent [57]. It has been recently patented for the treatment of stress-related depression [58]. The action of THIP on GABA_A receptors varies widely dependent upon the subunit composition [59]. While it is a partial agonist at the most ubiquitous subunit composition of $\alpha 1\beta 2\gamma 2$ (ED_{50} 143 μ M, I_{max} 76%), it is a full agonist at $\alpha 5$ containing GABA_A receptors (ED_{50} 28–129 μ M, I_{max} 93–99%) and a ‘super agonist’ at $\alpha 4\beta 3\delta$ GABA_A receptors (ED_{50} 6 μ M, I_{max} 163%) [60, 61]. THIP is, however, an antagonist at $\rho 1$ GABA_C receptors (IC_{50} 25 μ M) [62]. Clinical studies with THIP have indicated that sleep quality improving effects are obtained at plasma concentrations of the order of 1 μ M [63]. Classical benzodiazepine-sensitive, bicuculline-sensitive GABA_A receptors do not appear to be involved in the effects of THIP on pain perception and sleep. THIP-induced analgesia is not sensitive to the selective GABA_A antagonist bicuculline [64], and benzodiazepine-sensitive GABA_A receptors are not involved in the effects of THIP on sleep patterns [63]. Thus, bicuculline-insensitive, benzodiazepine-insensitive ρ -containing GABA_C receptors are possible candidates contributing to the effects of THIP on pain and/or sleep.

Aza-THIP, 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-3-ol (Fig. 2), is an analog of THIP that is inactive at GABA_A receptors but shows similar potency (K_i 31 μ M) to THIP as a GABA_C receptor antagonist [62]. Aza-THIP may be a useful tool for molecular and behavioural pharmacological studies, particularly in distinguishing the GABA_C antagonist effects of THIP from its GABA_A agonist/partial agonist action.

Insights into the molecular basis of the distinct antagonist properties of GABA_A and GABA_C receptors have been made via mutation and modelling studies [65]. Single mutations at each of nine residues in $\rho 1$ GABA_C receptors were unable to impart dramatic sensitivity to the classic GABA_A receptor antagonist bicuculline, which is inactive at wild type $\rho 1$ GABA_C receptors. A GABA_C triple mutant Y106S F138Y FYS240VF however exhibited relative high bicuculline sensitivity (K_i 29 μ M), compared to the bicuculline sensitivity of the wild-type GABA_A receptor (K_i 5 μ M) [65]. Similar studies with gabazine, a potent

antagonist at wild type GABA_A receptors (K_i 0.12 μ M) with much lower activity at wild type GABA_C receptors (K_i 58 μ M), showed that GABA_C sensitivity could be imparted by the mutations Y106S, F138Y, and Y102F. For the GABA_C receptor antagonist 3-aminopropylphosphonic acid (3-APA), its sensitivity was mainly dependent on residues Tyr102, Val140, FYS240–242, and Phe138. Thus, the residues Tyr102, Tyr106, Phe138, and FYS240–242 in the $\rho 1$ GABA_C receptors are major determinants for GABA_C antagonist properties distinct from those in the GABA_A receptors [65]. Unfortunately these studies were not extended to TPMPPA, the most widely used GABA_C receptor antagonist due to the then commercial unavailability of TPMPPA in the USA [65].

A model of the molecular basis for agonist and antagonist actions at GABA_C receptors predicts distinctive conformations of loop C, with agonists eliciting loop C closure, while antagonists interacted with a more open loop C [6]. This and other models of the GABA_C receptors [38, 66–68] seek to integrate computational and experimental data to aid the discovery of important interactions with existing neurochemicals known to influence GABA_C receptor function and to design new, more selective agents. Of particular interest are enantiomers that show contrasting effects including *cis*-constrained and flexible 2-substituted GABA analogs [69] and 3-hydroxy-substituted GABA analogs [70] with competing interactions at the GABA binding pocket where steric bulk on one side favours agonist action while steric bulk on the other side favours antagonist action.

Positive Modulators

While positive modulation by a variety of neurochemicals including barbiturates, benzodiazepines, flavonoids and steroids is a hallmark of GABA_A receptors, it is relatively rare concerning GABA_C receptors [18].

Certain steroids, such as allopregnanolone, 3 α -hydroxy-5 α -pregnan-20-one (Fig. 3), do act as positive modulators of wild type GABA_C receptors but only at μ M concentrations, whereas steroids act on GABA_A receptors at nM concentrations [71, 72]. Structure–activity studies have shown that the interactions of steroids with GABA_C receptors are complex. In general, in a pair of steroids active at GABA_C receptors with identical structures except for the stereochemistry at the C5-position, the 5 α -isomer acted as a positive modulator while the 5 β -isomer was a negative modulator [72]. This highlights a major difference between steroid actions on GABA_C and GABA_A receptors in addition to differences in potency and efficacy: 5 β -isomers negatively modulate GABA_C receptors and positively modulate GABA_A receptors [72].




Fig. 3 Structures of some positive and negative modulators of the activation of GABA_C receptors

It is possible to confer a degree of positive modulation by barbiturates by introducing mutations into GABA_C receptors but such modulation is a pale imitation of that observed in wild type GABA_A receptors. A single mutation of an isoleucine to serine (I307S) in TM2 of wild type GABA_C receptors enables pentobarbitone to act as a relatively weak positive modulator (EC₅₀ 226 μM) [73]. Similarly, a mutation of tryptophan 328 in TM3 to a spectrum of amino acids confers weak sensitivity to positive modulation by pentobarbitone [74]. Thus, serine 307 and tryptophan 328 contribute to the lack of positive modulation by barbiturates of GABA_C receptors. A double mutation of these amino acids, ρ1 I307S/W328 M, is necessary to confer positive modulation by diazepam and such modulation is low affinity and flumazenil-insensitive [75]. Neither of the single mutants I307S nor W328 M is sensitive to modulation by diazepam.

Taurine is a weak agonist at ρ1 GABA_C receptors, EC₅₀ 5 mM [76]. Co-applied with GABA, however, taurine at 0.3–30 μM acts as a positive modulator of the activation by GABA. Given the abundance of taurine in the retina, these observations suggest that taurine may play an important role in modulating retinal transmission mediated via GABA_C receptors [76]. Analogs of taurine may be worth

exploring as positive modulators of GABA_C receptors activation.

Negative Modulators

Epipregnanolone, 3β-hydroxy-5β-pregnan-20-one (Fig. 3), is an example of a number of steroids that are weak negative modulators of GABA_C receptor activation [71, 72]. Sulfated steroids, such as pregnenolone sulfate, 3β-sulfoxypregn-5-en-20-one (Fig. 3), also negatively modulate GABA_C receptor activation, less potently than they negatively modulate GABA_A receptors [72]. Surprisingly, 17β-estradiol (Fig. 3) is a negative modulator of GABA_C receptor activation, although it is relatively inactive at GABA_A receptors and positively modulates human α4β2 nicotinic receptors [72]. From such studies it appears that steroids interact with multiple sites on GABA_C receptors that differ from steroid modulatory sites on other members of the nicotinicoid receptor superfamily.

Loreclezole has been described as a ‘simple functional marker for homomeric GABA_C receptors’ based on its ability to negatively modulate (IC₅₀ 0.5 μM) recombinant ρ1 GABA_C receptors [77]. It is known as a potent positive modulator of GABA_A receptors containing β2 or β3 but not β1 subunits [78]. In addition to many neurosteroids, several neurochemicals are known to act as potent positive modulators of GABA_A receptors but act as weaker negative modulators of GABA_C receptors, including (+)-ROD188, pentobarbitone and propofol [73, 77].

Cyclothiazide is a negative modulator of perch ρ2 GABA_C receptors (IC₅₀ 12 μM) without effect on human ρ1 receptors [79]. In addition to its widespread use as a positive modulator of AMPA receptors, cyclothiazide is a potent negative modulator of GABA_A receptors [80]. The differential effect of cyclothiazide on human ρ1 and perch ρ2 GABA_C receptors may be attributed to a serine residue at the 2' position in the second transmembrane domain. It would be interesting to know what effect cyclothiazide has on human as distinct from perch ρ2 GABA_C receptors.

Some flavonoids such as apigenin act as negative modulators of ρ1 GABA_C receptor activation [81] in contrast to their complex modulatory effects on GABA_A receptors [82]. Many more flavonoids have been tested on GABA_A receptors than on GABA_C receptors.

Picrotoxinin and related cage compounds such as bilobalide negatively modulate GABA_C receptors by acting in the ion channel in a manner similar but not identical to the manner in which such compounds negatively modulate GABA_A, 5-HT_{3A} and most glycine receptors [83, 84].

Ethanol and related alcohols act as negative modulators of GABA_C receptors [85, 86], whereas they act as positive

modulators of GABA_A receptors particularly those containing δ -subunits [87, 88].

Conclusions

Given their less widespread distribution, lower abundance and relative structural simplicity compared to GABA_A and GABA_B receptors, GABA_C receptors are attractive drug targets. Considerable progress has been made in the discovery of neurochemicals with which to probe GABA_C receptor function and as leads for drug development. It is already clear that GABA_C receptors are very different from GABA_A and GABA_B receptors in terms of agonist, antagonist and modulator profiles. The development of subtype-selective agents for $\rho 1$, $\rho 2$, $\rho 3$ and combinations thereof GABA_C receptors is an urgent need.

References

- Gibbs ME, Johnston GAR (2005) Opposing roles for GABA_A and GABA_C receptors in short-term memory formation in young chicks. *Neuroscience* 131:567–576
- Chebib M, Hinton T, Schmid KL et al (2009) Novel, potent, and selective GABA_C antagonists inhibit myopia development and facilitate learning and memory. *J Pharmacol Exp Ther* 328: 448–457
- Froestl W, Markstein R, Schmid KL et al (2004) GABA_C antagonists for the treatment of myopia. *PCT Int Appl*:20030627
- Reis GM, Duarte ID (2007) Involvement of chloride channel coupled GABA_C receptors in the peripheral antinociceptive effect induced by GABA_C receptor agonist cis-4-aminocrotonic acid. *Life Sci* 80:1268–1273
- Arnaud C, Gauthier P, Gottesmann C (2001) Study of a GABA_C receptor antagonist on sleep-waking behavior in rats. *Psychopharmacology (Berl)* 154:415–419
- Abdel-Halim H, Hanrahan JR, Hibbs DE et al (2008) A molecular basis for agonist and antagonist actions at GABA_C receptors. *Chem Biol Drug Des* 71:306–327
- Johnston GAR, Curtis DR, Beart PM et al (1975) Cis- and trans-4-aminocrotonic acid as GABA analogues of restricted conformation. *J Neurochem* 24:157–160
- Drew CA, Johnston GAR, Weatherby RP (1984) Bicuculline-insensitive GABA receptors: studies on the binding of (–)-baclofen to rat cerebellar membranes. *Neurosci Lett* 52:317–321
- Cutting GR, Lu L, O'Hara BF et al (1991) Cloning of the γ -aminobutyric acid (GABA) $\rho 1$ cDNA: a GABA receptor subunit highly expressed in the retina. *Proc Natl Acad Sci USA* 88:2673–2677
- Polenzani L, Woodward RM, Miledi R (1991) Expression of mammalian γ -aminobutyric acid receptors with distinct pharmacology in *Xenopus* oocytes. *Proc Natl Acad Sci USA* 88: 4318–4322
- Cutting GR, Curristin S, Zoghbi H et al (1992) Identification of a putative γ -aminobutyric acid (GABA) receptor subunit $\rho 2$ cDNA and colocalization of the genes encoding $\rho 2$ (GABRR2) and $\rho 1$ (GABRR1) to human chromosome 6q14–q21 and mouse chromosome 4. *Genomics* 12:801–806
- Ogurusu T, Shingai R (1996) Cloning of a putative γ -aminobutyric acid (GABA) receptor subunit $\rho 3$ cDNA. *Biochim Biophys Acta* 1305:15–18
- Chebib M, Johnston GAR (2000) GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. *J Med Chem* 43:1427–1447
- Bailey M, Albrecht BE, Johnson KJ et al (1999) Genetic linkage and radiation hybrid mapping of the three human GABA_C receptor ρ subunit genes: GABRR1, GABRR2 and GABRR3. *Biochim Biophys Acta Gene Struct Expr* 1447:307–312
- Ogurusu T, Yanagi K, Watanabe M et al (1999) Localization of GABA receptor $\rho 2$ and $\rho 3$ subunits in rat brain and functional expression of homooligomeric $\rho 3$ receptors and heterooligomeric $\rho 2$ $\rho 3$ receptors. *Recept Channels* 6:463–475
- Liu B, Hattori N, Jiang B et al (2004) Single cell RT-PCR demonstrates differential expression of GABA_C receptor ρ subunits in rat hippocampal pyramidal and granule cells. *Brain Res Mol Brain Res* 123:1–6
- Koulen P, Brandstatter JH, Enz R et al (1998) Synaptic clustering of GABA_C receptor ρ -subunits in the rat retina. *Eur J Neurosci* 10:115–127
- Johnston GAR (2002) Medicinal chemistry and molecular pharmacology of GABA_C receptors. *Curr Top Med Chem* 2:897–907
- Bormann J, Feigenspan A (2001) GABA_C receptors: structure, function and pharmacology. *Hndb Expt Pharmac* 150:271–296
- McCall MA, Lukasiewicz PD, Gregg RG et al (2002) Elimination of the $\rho 1$ subunit abolishes GABA_C receptor expression and alters visual processing in the mouse retina. *J Neurosci* 22:4163–4174
- Zheng W, Zhao X, Wang J et al (2010) Retinal vascular leakage occurring in GABA $\rho 1$ subunit deficient mice. *Exp Eye Res* 90:634–640
- Chen Y, Zhou D, Zhou K et al (2007) Study on olfactory function in GABA_C receptor/channel $\rho 1$ subunit knockout mice. *Neurosci Lett* 427:10–15
- Schlicker K, McCall MA, Schmidt M (2009) GABA_C receptor-mediated inhibition is altered but not eliminated in the superior colliculus of GABA_C $\rho 1$ knockout mice. *J Neurophysiol* 101:2974–2983
- Klein RD, Brennan TJ (2002) Disruptions in GABA receptor $\rho 2$ subunit. Methods and uses thereof. Patent:WO/2002/079380
- Alakuijala A, Alakuijala J, Pasternack M (2006) Evidence for a functional role of GABA receptors in the rat mature hippocampus. *Eur J Neurosci* 23:514–520
- Xu JY, Yang B, Sastry BR (2009) The involvement of GABA_C receptors in paired-pulse depression of inhibitory postsynaptic currents in rat hippocampal CA1 pyramidal neurons. *Exp Neurol* 216:243–246
- Boue-Grabot E, Taupignon A, Tramu G et al (2000) Molecular and electrophysiological evidence for a GABA_C receptor in thyrotropin-secreting cells. *Endocrinology* 141:1627–1632
- Rozzo A, Ballerini L, Nistri A (1999) Antagonism by (1,2,5,6-tetrahydropyridine-4-yl) methylphosphinic acid of synaptic transmission in the neonatal rat spinal cord in vitro: an electrophysiological study. *Neuroscience* 90:1085–1092
- Fletcher EL, Clark MJ, Senior P et al (2001) Gene expression and localization of GABA_C receptors in neurons of the rat gastrointestinal tract. *Neuroscience* 107:181–189
- Zizzo MG, Mule F, Serio R (2007) Functional evidence for GABA as modulator of the contractility of the longitudinal muscle in mouse duodenum: role of GABA_A and GABA_C receptors. *Neuropharmacology* 52:1685–1690
- Kusama T, Spivak CE, Whiting P et al (1993) Pharmacology of GABA $\rho 1$ and GABA α/β receptors expressed in *Xenopus* oocytes and COS cells. *Br J Pharmacol* 109:200–206

32. Kusama T, Wang TL, Guggino WB et al (1993) GABA ρ 2 receptor pharmacological profile: GABA recognition site similarities to ρ 1. *Eur J Pharmacol* 245:83–84
33. Johnston GAR, Stephanson AL (1976) Inhibitors of the glial uptake of β -alanine in rat brain slices. *Brain Res* 102:374–378
34. Biedermann B, Eberhardt W, Reichelt W (1994) GABA uptake into isolated retinal Muller glial cells of the guinea-pig detected electrophysiologically. *Neuroreport* 5:438–440
35. Kragler A, Hofner G, Wanner KT (2005) Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4. *Eur J Pharmacol* 519:43–47
36. Wall MJ (2001) Cis-4-amino-crotonic acid activates alpha 6 subunit-containing GABA_A but not GABA_C receptors in granule cells of adult rat cerebellar slices. *Neurosci Lett* 316:37–40
37. Duke RK, Chebib M, Balcar VJ et al (2000) (+)- and (-)-cis-2-Aminomethylcyclopropanecarboxylic acids show opposite pharmacology at recombinant ρ (1) and ρ (2) GABA_C receptors. *J Neurochem* 75:2602–2610
38. Madsen C, Jensen AA, Liljefors T et al (2007) 5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel γ -aminobutyric acid_C receptor agonists. *J Med Chem* 50:4147–4161
39. Johnston GAR (1996) GABA_A receptor pharmacology. *Pharmacol Ther* 69:173–198
40. Murata Y, Woodward RM, Miledi R et al (1996) The first selective antagonist for a GABA_C receptor. *Bioorg Med Chem Lett* 6:2073–2076
41. Ragozzino D, Woodward RM, Murata Y et al (1996) Design and in vitro pharmacology of a selective γ -aminobutyric acid_C receptor antagonist. *Mol Pharmacol* 50:1024–1030
42. Chebib M, Mewett KN, Johnston GAR (1998) GABA_C receptor antagonists differentiate between human ρ 1 and ρ 2 receptors expressed in *Xenopus* oocytes. *Eur J Pharmacol* 357:227–234
43. Vien J, Duke RK, Mewett KN et al (2002) trans-4-Amino-2-methylbut-2-enoic acid (2-MeTACA) and (\pm)-trans-2-amino-methylcyclopropanecarboxylic acid (\pm)-TAMP can differentiate rat ρ 3 from human ρ 1 and ρ 2 recombinant GABA_C receptors. *Br J Pharmacol* 135:883–890
44. Matsui K, Hasegawa J, Tachibana M (2001) Modulation of excitatory synaptic transmission by GABA_C receptor-mediated feedback in the mouse inner retina. *J Neurophysiol* 86:2285–2298
45. Denter DG, Heck N, Riedemann T et al (2010) GABA_C receptors are functionally expressed in the intermediate zone and regulate radial migration in the embryonic mouse neocortex. *Neuroscience* 167:124–134
46. Harvey VL, Duguid IC, Krasel C et al (2006) Evidence that GABA ρ subunits contribute to functional ionotropic GABA receptors in mouse cerebellar Purkinje cells. *J Physiol (Lond)* 577:127–139
47. Schlicker K, Boller M, Schmidt M (2004) GABA_C receptor mediated inhibition in acutely isolated neurons of the rat dorsal lateral geniculate nucleus. *Brain Res Bull* 63:91–97
48. Schmidt M, Boller M, Ozen G et al (2001) Disinhibition in rat superior colliculus mediated by GABA_C receptors. *J Neurosci* 21:691–699
49. Nakayama Y, Hattori N, Otani H et al (2006) γ -aminobutyric acid (GABA)-C receptor stimulation increases prolactin (PRL) secretion in cultured rat anterior pituitary cells. *Biochem Pharmacol* 71:1705–1710
50. Krehan D, Frølund B, Krogsgaard-Larsen P et al (2003) Phosphinic, phosphonic and seleninic acid bioisosteres of isonipicotic acid as novel and selective GABA_C receptor antagonists. *Neurochem Int* 42:561–565
51. Chebib M, Vandenberg RJ, Froestl W et al (1997) Unsaturated phosphinic analogues of γ -aminobutyric acid as GABA_C receptor antagonists. *Eur J Pharmacol* 329:223–229
52. Froestl W, Mickel SJ, Von Sprecher G et al (1995) Phosphinic acid analogues of GABA 2. Selective, orally active GABA_B antagonists. *J Med Chem* 38:3313–3331
53. Froestl W, Gallagher M, Jenkins H et al (2004) SGS742: the first GABA_B receptor antagonist in clinical trials. *Biochem Pharmacol* 68:1479–1487
54. Chebib M, Johnston GAR, Hanrahan JR (2003) Neurologically active compounds. WO Patent 03/045897-A1
55. Chebib M, Kumar RJ, Johnston GAR (2006) Neurologically active compounds. WO Patent:2006/000043
56. Krogsgaard-Larsen P, Frølund B, Liljefors T et al (2004) GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. *Biochem Pharmacol* 68:1573–1580
57. Ebert B, Anderson NJ, Cremers TI et al (2008) Gaboxadol—a different hypnotic profile with no tolerance to sleep EEG and sedative effects after repeated daily dosing. *Pharmacol Biochem Behav* 90:113–122
58. Ebert B, Madsen TM (2009) Use of gaboxadol for the manufacture of a medicament for treat stress-mediated depression. WO Patent:2009/021521
59. Ebert B, Whiting PJ, Krogsgaard-Larsen P et al (1994) Molecular pharmacology of γ -aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different α , β , and γ receptor subunit combinations. *Mol Pharmacol* 46:957–963
60. Brown N, Kerby J, Bonnert TP et al (2002) Pharmacological characterization of a novel cell line expressing human alpha(4)-beta(3)delta GABA_A receptors. *Br J Pharmacol* 136:965–974
61. Mortensen M, Ebert B, Wafford K et al (2010) Distinct activities of GABA agonists at synaptic- and extrasynaptic-type GABA_A receptors. *J Physiol (Lond)* 588:1251–1268
62. Krehan D, Frølund B, Ebert B et al (2003) Aza-THIP and related analogues of THIP as GABA_C antagonists. *Bioorg Med Chem* 11:4891–4896
63. Faulhaber J, Steiger A, Lancel M (1997) The GABA_A agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. *Psychopharmacology (Berl)* 130:285–291
64. Zorn SH, Enna SJ (1987) The GABA agonist THIP attenuates antinociception in the mouse by modifying central cholinergic transmission. *Neuropharmacology* 26:433–437
65. Zhang J, Xue F, Chang Y (2008) Structural determinants for antagonist pharmacology that distinguish the ρ 1 GABA_C receptor from GABA_A receptors. *Mol Pharmacol* 74:941–951
66. Harrison NJ, Lummis SC (2006) Molecular modeling of the GABA_C receptor ligand-binding domain. *J Mol Mod* 12:317–324
67. Osolodkin DI, Chupakhin VI, Palyulin VA et al (2009) Molecular modeling of ligand-receptor interactions in GABA_C receptor. *J Mol Graph Model* 27:813–821
68. Adamian L, Gussin HA, Tseng YY et al (2009) Structural model of ρ 1 GABA_C receptor based on evolutionary analysis: testing of predicted protein-protein interactions involved in receptor assembly and function. *Protein Sci* 18:2371–2383
69. Crittenden DL, Park A, Qiu J et al (2006) Enantiomers of cis-constrained and flexible 2-substituted GABA analogues exert opposite effects at recombinant GABA_C receptors. *Bioorg Med Chem* 14:447–455
70. Hinton T, Chebib M, Johnston GA (2008) Enantioselective actions of 4-amino-3-hydroxybutanoic acid and (3-amino-2-hydroxypropyl)methylphosphinic acid at recombinant GABA_C receptors. *Bioorg Med Chem Lett* 18:402–404
71. Morris K, Moorefield CN, Amin J (1999) Differential modulation of the γ -aminobutyric acid type C receptor by neuroactive steroids. *Mol Pharmacol* 56:752–759
72. Li W, Jin X, Covey DF et al (2007) Neuroactive steroids and human recombinant ρ 1 GABA_C receptors. *J Pharmacol Exp Ther* 323:236–247

73. Belelli D, Pau D, Cabras G et al (1999) A single amino acid confers barbiturate sensitivity upon the GABA $\rho(1)$ receptor. *Br J Pharmacol* 127:601–604
74. Amin J (1999) A single hydrophobic residue confers barbiturate sensitivity to γ -aminobutyric acid type C receptor. *Mol Pharmacol* 55:411–423
75. Walters RJ, Hadley SH, Morris KDW et al (2000) Benzodiazepines act on GABA_A receptors via two distinct and separable mechanisms. *Nat Neurosci* 3:1274–1281
76. Ochoa-de la Paz LD, Martinez-Davila IA, Miledi R et al (2008) Modulation of human GABA $\rho 1$ receptors by taurine. *Neurosci Res* 61:302–308
77. Thomet U, Baur R, Dodd RH et al (2000) Loreclezole as a simple functional marker for homomeric ρ type GABA_C receptors. *Eur J Pharmacol* 408:R1–R2
78. Wingrove PB, Wafford KA, Bain C et al (1994) The modulatory action of loreclezole at the γ -aminobutyric acid type A receptor is determined by a single amino acid in the $\beta 2$ and $\beta 3$ subunit. *Proc Natl Acad Sci USA* 91:4569–4573
79. Xie A, Song X, Ripps H et al (2008) Cyclothiazide: a subunit-specific inhibitor of GABA_C receptors. *J Physiol (Lond)* 586: 2743–2752
80. Deng L, Chen G (2003) Cyclothiazide potently inhibits γ -aminobutyric acid type A receptors in addition to enhancing glutamate responses. *Proc Natl Acad Sci USA* 100:13025–13029
81. Goutman JD, Waxemberg MD, Donate-Oliver F et al (2003) Flavonoid modulation of ionic currents mediated by GABA_A and GABA_C receptors. *Eur J Pharmacol* 461:79–87
82. Campbell EL, Chebib M, Johnston GAR (2004) The dietary flavonoids apigenin and (-)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA_A receptors. *Biochem Pharmacol* 68:1631–1638
83. Huang SH, Duke RK, Chebib M et al (2006) Mixed antagonistic effects of bilobalide at $\rho 1$ GABA_C receptor. *Neuroscience* 137:607–617
84. Carland JE, Johnston GAR, Chebib M (2008) Relative impact of residues at the intracellular and extracellular ends of the human GABA_C $\rho 1$ receptor M2 domain on picrotoxinin activity. *Eur J Pharmacol* 580:27–35
85. Mihic SJ, Harris RA (1996) Inhibition of $\rho 1$ receptor GABAergic currents by alcohols and volatile anesthetics. *J Pharmacol Exp Ther* 277:411–416
86. Krasowski MD, Finn SE, Ye Q et al (1998) Trichloroethanol modulation of recombinant GABA_A, glycine and GABA $\rho 1$ receptors. *J Pharmacol Exp Ther* 284:934–942
87. Wallner M, Hancher HJ, Olsen RW (2003) Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta γ -aminobutyric acid type A receptors at low concentrations known to affect humans. *Proc Natl Acad Sci USA* 100:15218–15223
88. Wei W, Faria LC, Mody I (2004) Low ethanol concentrations selectively augment the tonic inhibition mediated by delta subunit-containing GABA_A receptors in hippocampal neurons. *J Neurosci* 24:8379–8382